Pharmacological evaluation of 5-(Z,E)-13,14-didehydro-20-methyl-carboprostacyclin (FCE 22509)
- 31 March 1986
- journal article
- research article
- Published by Elsevier in Prostaglandins, Leukotrienes and Medicine
- Vol. 21 (3) , 231-245
- https://doi.org/10.1016/0262-1746(86)90045-4
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Hypotensive effect in the rat after oral prostacyclin (PGI2)Prostaglandins, Leukotrienes and Medicine, 1985
- A chemically stable analogue, 9 beta‐methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.British Journal of Clinical Pharmacology, 1984
- Inhibition of platelet aggregation by a new agent, 5-(Z,E)-13,14-didehydro-20-methyl-carbo PGI2 (FCE 22509)Prostaglandins, Leukotrienes and Medicine, 1984
- The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374) ? Equipotent to PGI2 in vitroNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1981
- Influence of pH on the prostacyclin (PGI2) mediated inhibition of platelet functionProstaglandins and Medicine, 1980
- Metabolism of prostacyclin in ratBiochemistry, 1978
- Reversal of platelet aggregation by prostacyclinPharmacological Research Communications, 1978
- Inhibition of human platelet aggregation by stable analogs of prostacyclinPharmacological Research Communications, 1977